Degeneracy, as opposed to specificity, in immunotherapy

Journal of Clinical Investigation

Volumn 109, Issue 5, 2002, Pages 581-584

  Hafler, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GLATIRAMER; PEPTIDE; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; BYSTANDER EFFECT; DRUG MECHANISM; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LIGAND BINDING; NONHUMAN; NOTE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0036194760     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215198     Document Type: Note

References (27)

1. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein
2. + T cell responses in patients with multiple sclerosis
3. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis
4. Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones
5. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone
6. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
7. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE
8. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
9. Weak peptide agonists reveal functional differences in B7-1 and B7-2 costimulation of human T cell clones
10. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand
11. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens
12. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein
13. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand
14. Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99
15. Cross-reactivity of T-cell clones specific for altered peptide ligands of myelin basic protein
16. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
17. Induction of a nonencephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
18. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients
19. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide
20. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules
21. Copolymer 1 reduces relapse rare and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial
22. Human and murine CD4 T cell reactivity to a complex antigen: Recognition of the synthetic random polypeptide glatiramer acetate
23. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
24. Multiple sclerosis: Comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells
25. Mechanisms of immunomodulation by glatiramer acetate
26. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells
27. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes